Laura J. Esserman


Director, Carol Franc Buck Breast Care Center

Dr. Laura Esserman, a nationally known breast surgeon, directs the UCSF Carol Franc Buck Breast Care Center at the Mount Zion campus. Her work is devoted to developing new, more effective ways to care for and empower breast cancer patients during treatment. She tailors treatments for individual patients using biology, personal preference and constant feedback regarding outcomes of care.

Esserman earned her undergraduate degree at Harvard University and completed her medical and surgical training at Stanford University. She completed a postdoctoral fellowship in breast oncology at Stanford and later earned a master's degree from the Stanford Graduate School of Business. She joined UCSF Medical Center in 1993.

  • Education

    Stanford University, 1983

  • Residencies

    Stanford University, General Surgery, 1991

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title


  • Languages


Clinics I work with

Breast Care Center

Berkeley Outpatient Center

3100 San Pablo Ave., Suite 430
Berkeley, CA 94702

My reviews


Overall Experience
80 Reviews
I wish every woman with breast cancer could see Dr. Esserman
Explained things in a way that was easy to understand
80 Reviews
Did the doctor pay attention to your concerns
80 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
78 Reviews
Knew the important information about your medical history
79 Reviews
The provider showed respect for what you had to say
80 Reviews
The provider spent enough time with me
80 Reviews
Decorative Caduceus

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Proportion of cancers diagnosed at Stage IIB or higher


Decorative Caduceus

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Time to achieve durable change in COVID-19 to ordinal level 4 or less for at least 48 hours


Decorative Caduceus

Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

To determine the maximum tolerated dose (MTD), and recommended dose for subsequent expansion cohort, of intralesionally administered pembrolizumab in patients with ductal carcinoma in situ (DCIS) of the breast.